Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

BRAF-mutated pleomorphic xanthoastrocytoma is associated with temporal location, reticulin fiber deposition and CD34 expression.

Koelsche C, Sahm F, Wöhrer A, Jeibmann A, Schittenhelm J, Kohlhof P, Preusser M, Romeike B, Dohmen-Scheufler H, Hartmann C, Mittelbronn M, Becker A, von Deimling A, Capper D.

Brain Pathol. 2014 Apr;24(3):221-9. doi: 10.1111/bpa.12111.

PMID:
24345274
2.

BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.

Lee D, Cho YH, Kang SY, Yoon N, Sung CO, Suh YL.

J Surg Oncol. 2015 Mar;111(3):359-64. doi: 10.1002/jso.23822.

PMID:
25346165
3.

Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression.

Chappé C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D.

Brain Pathol. 2013 Sep;23(5):574-83. doi: 10.1111/bpa.12048.

PMID:
23442159
4.

Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.

Kaulich K, Blaschke B, Nümann A, von Deimling A, Wiestler OD, Weber RG, Reifenberger G.

J Neuropathol Exp Neurol. 2002 Dec;61(12):1092-9.

5.

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A.

Acta Neuropathol. 2011 Mar;121(3):397-405. doi: 10.1007/s00401-011-0802-6.

PMID:
21274720
6.

BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.

Tabouret E, Bequet C, Denicolaï E, Barrié M, Nanni I, Metellus P, Dufour H, Chinot O, Figarella-Branger D.

Eur J Surg Oncol. 2015 Dec;41(12):1685-90. doi: 10.1016/j.ejso.2015.09.012.

PMID:
26454767
7.

Expression of the CD34 antigen in pleomorphic xanthoastrocytomas.

Reifenberger G, Kaulich K, Wiestler OD, Blümcke I.

Acta Neuropathol. 2003 Apr;105(4):358-64.

PMID:
12624789
8.

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.

Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S.

PLoS One. 2011 Mar 29;6(3):e17948. doi: 10.1371/journal.pone.0017948.

9.

Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.

Tanaka S, Nakada M, Nobusawa S, Suzuki SO, Sabit H, Miyashita K, Hayashi Y.

Brain Tumor Pathol. 2014 Jul;31(3):172-6. doi: 10.1007/s10014-014-0192-2.

PMID:
24894018
10.

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells.

Koelsche C, Wöhrer A, Jeibmann A, Schittenhelm J, Schindler G, Preusser M, Lasitschka F, von Deimling A, Capper D.

Acta Neuropathol. 2013 Jun;125(6):891-900. doi: 10.1007/s00401-013-1100-2.

PMID:
23435618
11.

Epithelioid GBMs show a high percentage of BRAF V600E mutation.

Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, Foreman NK.

Am J Surg Pathol. 2013 May;37(5):685-98. doi: 10.1097/PAS.0b013e31827f9c5e.

12.

Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.

Yamada S, Kipp BR, Voss JS, Giannini C, Raghunathan A.

Am J Surg Pathol. 2016 Feb;40(2):279-84. doi: 10.1097/PAS.0000000000000515.

PMID:
26414224
13.

Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three cases.

Aisner DL, Newell KL, Pollack AG, Kleinschmidt-Demasters BK, Steinberg GK, Smyth LT, Vogel H.

Clin Neuropathol. 2014 Mar-Apr;33(2):112-21. doi: 10.5414/NP300679.

14.
15.

Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Ida CM, Rodriguez FJ, Burger PC, Caron AA, Jenkins SM, Spears GM, Aranguren DL, Lachance DH, Giannini C.

Brain Pathol. 2015 Sep;25(5):575-86. doi: 10.1111/bpa.12217.

16.

Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma.

Ida CM, Vrana JA, Rodriguez FJ, Jentoft ME, Caron AA, Jenkins SM, Giannini C.

Acta Neuropathol Commun. 2013 May 30;1:20. doi: 10.1186/2051-5960-1-20.

17.

Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomas--Same Entity or First Cousins?

Alexandrescu S, Korshunov A, Lai SH, Dabiri S, Patil S, Li R, Shih CS, Bonnin JM, Baker JA, Du E, Scharnhorst DW, Samuel D, Ellison DW, Perry A.

Brain Pathol. 2016 Mar;26(2):215-23. doi: 10.1111/bpa.12295.

PMID:
26238627
18.

BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Kleinschmidt-DeMasters BK, Aisner DL, Foreman NK.

Am J Surg Pathol. 2015 Apr;39(4):528-40. doi: 10.1097/PAS.0000000000000363.

19.

Anaplastic PXA in adults: case series with clinicopathologic and molecular features.

Schmidt Y, Kleinschmidt-DeMasters BK, Aisner DL, Lillehei KO, Damek D.

J Neurooncol. 2013 Jan;111(1):59-69. doi: 10.1007/s11060-012-0991-4.

20.

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.

Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, Pichler J, Pusch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M.

Acta Neuropathol. 2012 Feb;123(2):223-33. doi: 10.1007/s00401-011-0887-y.

PMID:
22012135
Items per page

Supplemental Content

Support Center